Skip to content
value.today

VivoSim Labs, INC.

VIVS
$3 Mmarket cap on Oct 20, 2026
Compare
World rank
#27,328
Revenue
$0 M
For year ending March-2026
Net income
$-14 M
-10646.2% margin
SEC filing
Employees
15
As of June 1, 2026
SEC filing

VivoSim Labs, INC. in brief

VivoSim Labs, INC. is a listed company in the Biotechnology industry, based in San Diego, California, USA. Its market value was $3 M on 20 October 2026, which makes it the 27,328th largest listed company in the world and the 4,455th largest in the USA on this site. In the year to March 2026 it had sales of $0 M and a net loss of $14 M. It employs about 15 people. Its largest product and service lines by sales in 2026 were Royalty (100%). Its shares trade under the symbol VIVS (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About VivoSim Labs, INC.

VivoSim Labs, Inc., is a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional human tissue models of liver and intestine. We offer partners liver and intestinal toxicology insights using our new approach methodologies models. We anticipate accelerated adoption of human tissue models following the U.S. Food and Drug Administration announcement on April 10, 2025 to refine animal testing requirements in favor of these non-animal NAM methods. We also expect to offer bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of these complex human tissue models.

From the company's annual report filed with the US SEC: read the report

VivoSim Labs, INC. timeline

3 events, 2010–2025
  1. 2010
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2011
  4. ✎
    Renamed Organovo Holdings, Inc.
    Formerly Real Estate Restoration & Rental, Inc..
  5. 2025
  6. ✎
    Renamed VivoSim Labs, INC.
    Formerly Organovo Holdings, Inc..

Events of VivoSim Labs, INC. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$1 M$2 M$3 M$4 M

World rank over time

▼ down 236 places since 2026
2026-09-30: #27097#27,09720262026-10-20: #27333#27,3332026

Rank in USA: #4,372 (Sep 2026) · #4,457 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
25.0×
Price / book
—
Free cash flow yield
-333.2%
Net margin (TTM)
-7907.7%
Operating margin
-8838.5%
Return on equity
—
Liabilities / assets
114.7%
Revenue growth
-7.1%
R&D / revenue
3223.1%
Revenue per employee
$9 K
Profit per employee
$-923 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Mar 2019: revenue $3M, net income $-27M$3MFY19Fiscal year ending Mar 2020: revenue $2M, net income $-19M$2MFY20Fiscal year ending Mar 2021: revenue —, net income $-17M—FY21Fiscal year ending Mar 2022: revenue $2M, net income $-11M$2MFY22Fiscal year ending Mar 2023: revenue $0M, net income $-17M$0MFY23Fiscal year ending Mar 2024: revenue $0M, net income $-15M$0MFY24Fiscal year ending Mar 2025: revenue $0M, net income $-2M$0MFY25Fiscal year ending Mar 2026: revenue $0M, net income $-14M$0MFY26
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Mar 2026$0M-7.1%$-11M$-14M-10646.2%
Mar 2025$0M+27.3%$-13M$-2M-1778.6%
Mar 2024$0M-70.3%$-15M$-15M-13336.4%
Mar 2023$0M-75.3%$-18M$-17M-4664.9%
Mar 2022$2M—$-11M$-11M-763.3%
Mar 2021——$-17M$-17M—
Mar 2020$2M-28.8%$-21M$-19M-850.5%
Mar 2019$3M—$-27M$-27M-862.1%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Mar 2026$-11M$0M$-11M$-5.35—
Mar 2025$-9M$0M$-9M$-1.70—
Mar 2024$-15M$0M$-15M$-19.25—
Mar 2023$-12M$0M$-13M$-1.98—
Mar 2022$-8M$0M$-9M$-1.32—
Mar 2021$-13M$0M$-14M$-2.44—
Mar 2020$-15M$0M$-15M$-2.80—
Mar 2019$-20M$0M$-20M$-0.23—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$0M
Net income, trailing 12 months
$-10M
RevenueNet income
Three months to Dec 2024: revenue $0M, net income $-3M$0MDec ’24Three months to Mar 2025 (from the annual report): revenue $0M, net income $7M$0MMar ’25Three months to Jun 2025: revenue $0M, net income $-3M$0MJun ’25Three months to Sep 2025: revenue $0M, net income $-3M$0MSep ’25Three months to Dec 2025: revenue $0M, net income $-3M$0MDec ’25Three months to Mar 2026 (from the annual report): revenue $0M, net income $-6M$0MMar ’26Three months to Jun 2026: revenue $0M, net income $-1M$0MJun ’26Three months to Sep 2026: revenue $0M, net income $-0M$0MSep ’26

Latest quarter to Sep 2026: revenue $0M (+66.7% on a year earlier), net income $-0M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of VivoSim Labs, INC. with the US Securities and Exchange Commission.

Annual results

Revenue
$0 M
Operating income
$-11 M
Net income
$-14 M

For year ending March-2026 · source: SEC filing

Balance sheet

Total assets
$7 M
Total liabilities
$8 M
Total equity
$-1 M

As of March-2026

Top 27 institutional investors in VivoSim Labs, INC.#

As of Sep 30, 2026
27 institutions held 517,735 shares (about 2.5% of the shares outstanding) on Sep 30, 2026. The ten largest hold 2.5%. Source: SEC Form 13F filings, filed through Nov 18, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in VivoSim Labs, INC.
#InstitutionShares heldChange (shares)% heldValueFiled
1Armistice Capital, LLC390,431New1.93%$0 MNov 16, 2026
2Jane Street Group, LLC46,986New0.23%$0 MNov 12, 2026
3Geode Capital Management, LLC20,173-5,803 (-22.34%)0.10%$0 MNov 6, 2026
4Vanguard Capital Management LLC15,3710 (0.00%)0.08%$0 MNov 13, 2026
5TRUE Private Wealth Advisors10,895New0.05%$0 MOct 19, 2026
6BlackRock, Inc.10,342-1,475 (-12.48%)0.05%$0 MNov 13, 2026
7UBS Group AG9,118+9,100 (+50555.56%)0.04%$0 MNov 10, 2026
8Vanguard Fiduciary Trust Co7,0030 (0.00%)0.03%$0 MNov 13, 2026
9Tower Research Capital LLC (TRC)6,021+772 (+14.71%)0.03%$0 MNov 16, 2026
10Allworth Financial LP500New0.00%$0 MNov 17, 2026
11SBI Securities Co., Ltd.2210 (0.00%)0.00%$0 MOct 22, 2026
12Larson Financial Group LLC1660 (0.00%)0.00%$0 MNov 5, 2026
13Albion Financial Group /ut1590 (0.00%)0.00%$0 MOct 21, 2026
14Wells Fargo & Company/mn136+25 (+22.52%)0.00%$0 MNov 16, 2026
15Osaic Holdings, Inc.92+8 (+9.52%)0.00%$0 MNov 12, 2026
16Robinhood Markets, Inc.42—0.00%$0 MNov 18, 2026
17Morgan Stanley41-8 (-16.33%)0.00%$0 MNov 13, 2026
18IFG Advisory, LLC140 (0.00%)0.00%$0 MNov 9, 2026
19Jones Financial Companies Lllp8New0.00%$0 MNov 13, 2026
20Pinnacle Financial Group, Inc.6—0.00%$0 MNov 16, 2026
21Rockefeller Capital Management L.P.20 (0.00%)0.00%$0 MNov 13, 2026
22Golden State Wealth Management, LLC20 (0.00%)0.00%$0 MNov 2, 2026
23Activest Wealth Management20 (0.00%)0.00%$0 MOct 15, 2026
24Harbour Investments, Inc.10 (0.00%)0.00%$0 MNov 9, 2026
25Royal Bank Of Canada10 (0.00%)0.00%$0 MNov 16, 2026
Show all 27: investors 26 to 27
Institutional investors 26 to 27 in VivoSim Labs, INC.
#InstitutionShares heldChange (shares)% heldValueFiled
26Caitong International Asset Management Co., Ltd1-16 (-94.12%)0.00%$0 MOct 29, 2026
27Hilton Head Capital Partners, LLC10 (0.00%)0.00%$0 MOct 23, 2026

Mutual funds holding VivoSim Labs, INC.#

4 funds hold shares worth $0 M (about 0.2% of the company). Since their previous reports 2 added shares and 0 sold, buying $0 M net.
Mutual funds holding VivoSim Labs, INC.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC24,544$0 M0.12%<0.01%+11%May 31, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.15,371$0 M0.08%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC4,055$0 M0.02%<0.01%+126%May 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC991$0 M<0.01%<0.01%no changeMay 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 4 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at VivoSim Labs, INC.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$3 K
1 purchase, 1 insider
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$3 K
open market only
Insiders on file
22
since
$3 K-$32 K$0Nov 2023: bought $0 (0 trades), sold $32 K (1 trades)Nov 23Nov 2025: bought $0 (0 trades), sold $7 K (1 trades)NovAug 2026: bought $3 K (1 trades), sold $0 (0 trades)Aug
Bought (open market)Sold (open market)Hover a month for the totals
VivoSim Labs, INC.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Tony Serge LialinChief Commercial OfficerBuy+10,000$0.280$3 K10,000Form 4
filed Adam K. SternDirectorGrant or award+15,000——19,899Form 4
filed Douglas Jay CohenDirectorGrant or award+15,000——20,732Form 4
filed David GobelDirectorGrant or award+15,000——15,000Form 4
filed Alison Tjosvold MilhousDirectorGrant or award+15,000——19,899Form 4
filed Keith MurphyEXECUTIVE CHAIRMAN, DirectorGrant or award+15,000——26,053Form 4
filed David GobelDirectorSell+3,266$2.240$7 K0Form 4
filed Vaidehi JoshiDirectorGrant or award+19,607——58,821Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: VivoSim Labs, INC.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
649,569
22.4% of shares · 1 days to cover
Buybacks, Q1 2022
$0M
Q4 2022
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-12 reverse split in the period to ; 20-for-1 split

VivoSim Labs, INC. share buybacks by quarter
Buybacks, quarterFiscalSpent
Q1 2022Q4 2022$0M
Q4 2021Q3 2022$0M
Q1 2021Q4 2021$0M
Q4 2020Q3 2021$0M
Q1 2020Q4 2021$0M
Q4 2019Q3 2021$0M

Trading halts

  • 2026-07-15 13:34 UTC, code LUDP, resumed 13:39 UTC

Fails to deliver

  • : 27,406 shares at $0.16
  • : 47,179 shares at $0.16
  • : 67,128 shares at $0.17
  • : 8,396 shares at $0.20
  • : 31,594 shares at $0.26

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

VivoSim Labs, INC. scorecard#

Passes 2 of the 12 checks that could be worked out: strongest in financial health (1 of 3), weakest in valuation (0 of 4). Fiscal year 2025; market cap of Oct 20, 2026.

  • Valuation0 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
    • ✗Price to sales below its peers' median25.0×Price to sales 25.0× against Biotechnology's median of 8.7×.
    • –Free cash flow yield above 5%No free cash flow yield on file.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-5.35 vs -1.70Diluted EPS -5.35 in fiscal 2025 against -1.70 the year before (report's currency).
    • ✓Net income higher than five years earlier-$14 M-$14 M in fiscal 2025 against -$17 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 2
    • ✗Profitable in the newest year-$14 MNet income -$14 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities2.4×Current ratio 2.38 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-71.70Z-score -71.70 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year76.8%Diluted shares up 76.8% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

VivoSim Labs, INC.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

VivoSim Labs, INC.: statements by fiscal year
PeriodTrendFY 2025to Mar 31, 2026FY 2024to Mar 31, 2025FY 2023to Mar 31, 2024FY 2022to Mar 31, 2023FY 2021to Mar 31, 2022FY 2020to Mar 31, 2021FY 2019to Mar 31, 2020FY 2018to Mar 31, 2019FY 2017to Mar 31, 2018FY 2016to Mar 31, 2017
Income statement
Revenue0.10.10.10.41.502.23.14.64.2
Cost of revenue00.0———00.30.51.0r1.0
Research and development4.25.05.58.93.31.15.3151820
Selling, general and administrative7.47.79.79.29.71618152122
Total costs and expenses12131518131724304043
Operating income−11−13−15−18−11−17−21−27−35−39
Interest and finance income0.30.10.40.50.00.00.60.70.50.2
Interest expense and finance costs0.00.0———————0
Other non-operating income (expense)−2.4100.40.50.00.02.80.60.50.2
Income before tax−14−2.5————————
Income tax0.00.00.00.00.00.00.00.00.00.0
Net income including minority interests−14−2.5−15−17−11−17−19−27−35−38
Net income attributable to shareholders−14−2.5−15−17−11−17−19−27−35−38
Earnings per share, basic-5.35-1.70-19.25r-1.98-1.32-2.44-2.80r-0.23-0.32-0.39
Earnings per share, diluted-5.35-1.70-19.25r-1.98-1.32-2.44-2.80r-0.23-0.32-0.39
Shares, weighted average (basic)2.61.50.8r8.78.7—————
Shares, weighted average (diluted)2.61.50.8r8.78.76.96.5r11510798
Balance sheet
Cash and cash equivalents5.0112.915293727364463
Short-term investments————0—————
Receivables0.00.00.00.2000.10.50.90.6
Inventory000.30——00.50.80.6
Other current assets00.0r0.0r0.1r0.91.00.91.01.21.1
Current assets6.6123.917303828394765
Property, plant and equipment0.20.40.70.90.70.401.82.83.8
Right-of-use (leased) assets0.40.91.31.72.20—0r——
Total assets7.4156.320334028415069
Accounts payable1.01.60.60.30.40.30.70.60.51.2
Current liabilities2.83.71.93.71.40.71.83.74.76.0
Lease liabilities (non-current)00.40.91.31.70—0——
Total liabilities8.54.22.75.03.10.71.84.35.26.8
Retained earnings−356−342−340−325−308−296−279−261−234−199
Shareholders' equity−1.1103.615303927364562
Total equity−1.1103.615303927364562
Total liabilities and equity7.4156.320334028415069
Shares outstanding2.91.90.8r8.78.78.76.5r124111105
Cash-flow statement
Depreciation and amortization0.20.30.30.30.10.01.11.01.31.1
Share-based compensation0.30.51.52.42.35.64.15.26.97.4
Cash from operating activities−11−9.5−15−12−8.5−13−15−20−29−29
Capital expenditure0−0.0−0.0−0.4−0.4−0.40−0.1−0.2−1.4
Intangible assets bought———————0−0.10
Cash from investing activities0.19.00.8−1.0−0.4−0.40.7−0.1−0.3−1.4
Shares issued4.88.81.400.3245.0139.4—
Shares bought back————0−0.00———
Cash from financing activities4.48.81.400.2244.9131031
Exchange-rate effect on cash————————0.0−0.0
Change in cash−6.38.4−12−13−8.710−9.2−7.3−190.7
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What VivoSim Labs, INC. sells: revenue by product line, fiscal 2026#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2025. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Royalty$0 M100%

Source: SEC annual report (XBRL data) · as of Mar 31, 2026

Executive pay at VivoSim Labs, INC.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2026
$866 K
Mr. Murphy
Other top executives, average
$218 K
the CEO earned 4× this
$100 invested is now
$1
VivoSim Labs, INC.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2026Mr. Murphy$866 K$780 K$218 K$1
2025Mr. Murphy$1.2 M$888 K$136 K$2
2024Mr. Murphy$681 K$596 K$343 K$11

Source: SEC proxy statement (Form DEF 14A) · as of Mar 31, 2026

Events at VivoSim Labs, INC.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling
  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 4 · Acquisition or sale completed 1 · Directors and officers 5 · Material agreement 4 · Unregistered share sale 1 · Shareholder rights changed 1 · Bylaws or fiscal year changed 2 · Shareholder vote 3 · Results announced 2

VivoSim Labs, INC.: events reported to the SEC
FiledWhat happenedFiling
Material agreement8-K
Directors and officersShareholder vote8-K
Delisting notice8-K
Results announced8-K
Delisting notice8-K
Material agreementUnregistered share sale8-K
Material agreement8-K
Shareholder vote8-K
Directors and officers8-K
Bylaws or fiscal year changed8-K
Results announced8-K
Acquisition or sale completedDirectors and officers8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Delisting noticeMaterial agreement8-K
Delisting notice8-K
Directors and officers8-K
Directors and officersShareholder vote8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Oct 16, 2026

Acquisitions and funding#

Private share sales · funding history

Private share sales of VivoSim Labs, INC.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2012$8 MIssued in a merger or acquisition$2 to $10 million119equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Lobbying by VivoSim Labs, INC.#

$70 K spent on lobbying the US Congress and federal agencies in 2026, most often on health issues.

Lobbying, 2026
$70 K
#1,272 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2026
2026 so far
$70 K
  • Health Issues3 reports

Lobbying firms hired in 2026

TSG ADVOCATES DC, LLC $70 K

VivoSim Labs, INC.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2026 (so far)$70 K—3

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “VivoSim Labs, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

Layoffs at VivoSim Labs, INC.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
15
2017–2023
Latest
—
2023-08-16
VivoSim Labs, INC.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2023············—
2017········15···15
VivoSim Labs, INC.: latest layoffs
AnnouncedPeopleKindWhereSource
24% of workforceRestructuring planSEC 8-K“As previously disclosed in the Original Report, on August 18, 2023, the Company announced to its employees a plan to reduce the Company’s workforce, effective August 25, 2023, by a…”Filing
24% of workforceRestructuring planSEC 8-K“(the “Company”) announced to its employees a plan to reduce the Company’s workforce, effective August 25, 2023, by approximately six employees, which represents approximately 24% o…”Filing
15 peopleRestructuring planSEC 8-K“Under this plan, which is expected to be completed in November 2017, the Company will reduce its overall workforce by 15 employees (or 13%).”Filing

Source: State WARN notices and SEC 8-K item 2.05

How VivoSim Labs, INC. compares in Biotechnology

  • Market cap$3 M · higher than 3% of 726
  • Revenue$0 M · higher than 17% of 647
  • Revenue growth-7.1% · higher than 36% of 438
  • Price / sales25.0× · lower than 28% of 339

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
VivoSim Labs, INC.🇺🇸$3 M——-7.1%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 20, 2026
Annual results:
For year ending March-2026
Balance sheet:
As of March-2026
Employees:
As of June 1, 2026
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at VivoSim Labs, INC.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show VivoSim Labs, INC.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about VivoSim Labs, INC.? Suggest a correction